Latest Earnings Results: Q2 '26
Estimated EPS
-$0.04
Reported EPS
-$0.02
Surprise
+54.05%
Estimated Rev
$48.67M
Reported Rev
$51.44M
Surprise
+5.69%
• Reported GAAP EPS of -$0.08 up 70.37% YoY • Reported revenue of $51.44M up 8.53% YoY • Maravai LifeSciences maintains its 2026 revenue guidance range of $205.0 million to $215.0 million and raised its full year 2026 Adjusted EBITDA guidance to $33.0 million to $35.0 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.05 | -- | -- | N/A |
Q2 '26 | -$0.04 | -$0.02 | 54.05% | BEAT |
Q1 '26 | -$0.04 | $0.01 | 123.56% | BEAT |
Q4 '25 | -$0.07 | -$0.04 | 43.06% | BEAT |
Q3 '25 | -$0.08 | -$0.08 | 2.67% | BEAT |